

GENMAB A/S

ISIN: DK0010272202

WKN: -

Overview

2024/07/18 08:00:35

Price

244.30 EUR

Difference



-0.12% (-0.30)

General attributes

ISIN DK0010272202

Symbol GMAB

Exchange Hanover

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 16,155 EUR

Benchmark OMX COPENHAGEN 20

Market data

Bid (Bid size) -

Ask (Ask size) -

Open 244.30 EUR

High 244.30 EUR

Low 244.30 EUR

Close (prev. day) 244.60 EUR

VWAP -

Volume (pcs) 0

Trading volume 0.00

Number of trades 3

Last size 0

Futures and Options

Related Futures 12

Related Options -

PDF Downloads

Company report: GENMAB A/S



5Y



Information about previous performance does not guarantee future performance.

Source: FactSet

Recent research

| on sector | | | |
|------------|--|-----------------------|----------|
| Date | | Headline | Download |
| 2024/07/12 | | Global Equity Ratings | |
| 2024/06/21 | | Global Equity Ratings | |
| 2024/06/14 | | Global Equity Ratings | |
| 2024/05/29 | | Global Equity Ratings | |
| 2024/04/26 | | Global Equity Ratings | |

Details

2024/07/18 08:00:35

Price
244.30 EUR

Difference ▼ -0.12% (-0.30)

General attributes

| | |
|----------------|------------------------------------|
| ISIN | DK0010272202 |
| Symbol | GMAB |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 16,155 EUR |
| Benchmark | OMX COPENHAGEN 20 |

Market data

| | |
|-------------------|------------|
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 244.30 EUR |
| High | 244.30 EUR |
| Low | 244.30 EUR |
| Close (prev. day) | 244.60 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 3 |
| Last size | 0 |

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|--------|---------|------|
| Perf (%) | -7.81% | -31.53% | - |
| Perf (abs.) | -20.70 | -112.50 | - |
| Beta | 0.11 | 0.34 | 0.70 |
| Volatility | 30.18 | 33.79 | - |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|-------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 244.16 EUR (0) |
| Ø price 30 days Ø volume 30 days (pcs.) | 241.44 EUR (0) |
| Ø price 100 days Ø volume 100 days (pcs.) | 260.93 EUR (0) |
| Ø price 250 days Ø volume 250 days (pcs.) | 286.06 EUR (0) |
| YTD High date | 295.90 EUR (2024/01/09) |
| YTD Low date | 231.10 EUR (2024/07/03) |
| 52 Weeks High date | 380.10 EUR (2023/07/31) |
| 52 Weeks Low date | 231.10 EUR (2024/07/03) |

All listings for GENMAB A/S

| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-----------------------|------------|-------|--------------|-----------------------|------------------|
| Vienna Stock Exchange | 2024/07/18 | 17:32 | 249.40 EUR | 0.00 | 5 |
| Tradegate | 2024/07/18 | 22:26 | 249.50 EUR | 0.02 | 10 |
| Stuttgart | 2024/07/18 | 13:54 | 247.90 EUR | 0.00 | 8 |
| Nasdaq Copenhagen | 2024/07/18 | 17:20 | 1,851.50 DKK | 175.10 | 3,025 |

| | | | | | |
|---|----------------|-------|--------------|------|----|
| Munich | 2024/ 07/18 | 08:11 | 246.60 EUR | 0.00 | 2 |
| London Stock Exchange European Trade Reporting | 2024/ 07/18 | 16:55 | 1,851.75 DKK | 0.00 | 2 |
| Hanover | 2024/ 07/18 | 08:00 | 244.30 EUR | 0.00 | 3 |
| Frankfurt | 2024/ 07/18 | 21:49 | 247.60 EUR | 0.00 | 3 |
| FINRA other OTC Issues | 2024/ 07/18 | 21:19 | 267.19 USD | 0.14 | 20 |
| Duesseldorf | 2024/ 07/18 | 19:31 | 247.30 EUR | 0.00 | 7 |
| Berlin | 2024/ 07/18 | 21:43 | 248.90 EUR | 0.00 | 17 |

Company profile

Company Logo



Contact Details

GENMAB A/S

--

Carl Jacobsens Vej 30, Valby - 2500
Copenhagen

Telefon: +45-70-20-27-28

Fax: +

E-mail: info@genmab.com

PDF Downloads

Company report: GENMAB A/S



Company Profile

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Members of Management Board

Jan G. J. van de Winkel Chairman of Managing Board

Judith Klimovsky Member of Executive Committee

Martine J. van Vugt Member of Executive Committee

Anthony Mancini Member of Executive Committee

Anthony Pagano Member of Executive Committee

Birgitte Stephensen Member of Executive Committee

Christopher Cozic Member of Executive Committee

Tahamtan Ahmadi Member of Executive Committee

Board of directors

Deirdre Connelly Chairman of Supervisory Board

Anders Gersel Pedersen Member of Supervisory Board

Mijke Zachariasse Member of Supervisory Board

Paolo Augusto Paoletti Member of Supervisory Board

Elizabeth O'Farrell Member of Supervisory Board

Martin Schultz Member of Supervisory Board

Pernille Erenbjerg Member of Supervisory Board

Rolf K. Hoffmann Member of Supervisory Board

Takahiro Hamatani Member of Supervisory Board